Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Therapeutic Agent Characterization and Preclinical Efficacy Studies
This grant supports preclinical studies to evaluate the biological activity and efficacy of new therapeutic agents for neurological, aging, or pain-related disorders, with a focus on non-addictive treatments.
Funder: National Institutes of Health
Due Dates (Anticipated): September 2026 (Full application deadline, projected)
Funding Amounts: Not specified; award ceiling/floor and total program funding not yet announced.
Summary: Supports preclinical pharmacodynamic, pharmacokinetic, and efficacy studies of therapeutic agents (small molecules or biologics) to advance treatments for neurological and related disorders.
Key Information: This is a forecasted opportunity; applications are not being solicited yet.
Description
This program, led by the National Institutes of Health (NIH) through the National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Aging, the NIH HEAL (Helping to End Addiction Long-term) Initiative, and other participating Institutes and Centers, aims to support research on the characterization and preclinical efficacy of therapeutic agents. The focus is on pharmacodynamic, pharmacokinetic, and efficacy studies to demonstrate sufficient biological activity for further development as therapeutics for neurological disorders or non-opioid analgesic therapeutics with low addiction liability. Eligible projects may include studies of small molecules or biologics, with efficacy testing in validated in vivo models or New Approach Methodologies (NAMs).
